🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

16+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 16 of 16 recruiting trials for “small-cell-carcinoma-of-the-ovary”

Phase 1RecruitingNCT07424547 ↗

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

🏥 Conjupro Biotherapeutics, Inc.📍 5 sites📅 Started Mar 2026View details ↗
Phase 1RecruitingNCT07444814 ↗

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

👨‍⚕️ Margaret C Dugan, MD, Whitehawk Therapeutics📍 12 sites📅 Started Dec 2025View details ↗
Phase 1Enrolling by InvitationNCT07218003 ↗

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

👨‍⚕️ Thomas Manley, MD, Rondo Therapeutics📍 7 sites📅 Started Nov 2025View details ↗
Phase 1RecruitingNCT06774963 ↗

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

🏥 NextCure, Inc.📍 14 sites📅 Started Jan 2025View details ↗
Phase 2RecruitingNCT06677190 ↗

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

👨‍⚕️ Panagiotis Konstantinopoulos, MD, PhD, Dana-Farber Cancer Institute📍 2 sites📅 Started Dec 2024View details ↗
Phase 1, PHASE2RecruitingNCT06873555 ↗

A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors

🏥 Heronova Pharmaceuticals📍 2 sites📅 Started Sep 2024View details ↗
Phase 2RecruitingNCT06161532 ↗

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

👨‍⚕️ Andrea B Apolo, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Aug 2024View details ↗
Phase 2RecruitingNCT06228066 ↗

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

👨‍⚕️ Andrea B Apolo, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Jun 2024View details ↗
Phase 1RecruitingNCT06257264 ↗

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

👨‍⚕️ Study Director, BeiGene📍 24 sites📅 Started Mar 2024View details ↗
Phase 1, PHASE2RecruitingNCT06065462 ↗

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

👨‍⚕️ Amir Jazaeri, M D, M.D. Anderson Cancer Center📍 1 site📅 Started Nov 2023View details ↗
RecruitingNCT06279104 ↗

A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary

🏥 Tongji Hospital📍 1 site📅 Started Mar 2023View details ↗
Phase 2RecruitingNCT05312671 ↗

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

👨‍⚕️ Jean Hoffman-Censits, MD, Johns Hopkins University📍 2 sites📅 Started Jun 2022View details ↗
RecruitingNCT05621837 ↗

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

👨‍⚕️ Licia Rivoltini, Fondazione IRCCS Istituto Nazionale Tumori - Milan📍 1 site📅 Started Mar 2022View details ↗
Phase 1RecruitingNCT05104515 ↗

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

🏥 Oxford Vacmedix UK Ltd.📍 4 sites📅 Started Nov 2021View details ↗
Phase 2RecruitingNCT04602377 ↗

Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT

👨‍⚕️ Patricia PAUTIER, MD, PhD, Gustave Roussy, Cancer Campus, Grand Paris📍 13 sites📅 Started Aug 2021View details ↗
Phase 1, PHASE2RecruitingNCT04104776 ↗

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

👨‍⚕️ Novartis Pharmaceuticals, Novartis Pharmaceuticals📍 60 sites📅 Started Sep 2019View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →